An analysis of results from 3 clinical trials demonstrated that pegaspargase is cost-effective, improved quality-adjusted life-years, and was the dominant therapy in comparisons with native asparagine in multiple scenarios.
Pegvorhyaluronidase alfa is an enzyme that breaks down hyaluronan, thought to be a contributor to the structure of the tumor microenvironment in some pancreatic cancers.
Researchers hypothesized that because prior studies have demonstrated that common drugs can affect the microbiome, these medications could also impact IO efficacy in HCC.
Previous genomic profiling studies have identified potentially targetable alterations in IDH1 and FGFR2 in primary tumor specimens of some patients with IHCC.
Even though older adults were prescribed second-line therapies less frequently than younger adults, patients had similar overall survival outcomes across age subgroups.
A study evaluated contributions of physical and psychological symptoms, and pre-existing comorbidities to employment status following treatment for breast cancer.
This single-arm, phase 2 study of pembrolizumab in advanced solid tumor cancers did not limit patient enrollment based on tumor PD-L1 expression level.
The randomized, phase 3 BEACON CRC trial was a 3-arm study conducted in patients with pretreated metastatic CRC characterized by a BRAF V600E mutation.
In a study, localized prostate cancer patients reported clinically meaningful differences in urinary, bowel, sexual, and hormonal function by management option up to 5 years of follow-up.
Pelvic physical therapy may be more appropriate than Kegel exercises in managing post-radical prostatectomy pain and stress urinary incontinence, according to a new study.
Toxicity profile and readmission rates among patients who underwent radical cystectomy and pelvic lymph node dissection following neoadjuvant pembrolizumab are in line with previously published series reporting 90-day outcomes after RC with or without neoadjuvant chemotherapy.
The study’s primary endpoint was efficacy, determined by complete remission, peripheral blood cell count remission, quality of life, and JAK2 V617F allele burden.
